Bespak, a division of Consort Medical, has received a contract to develop a nasal drug delivery device.

Bespak develops drug delivery devices with a focus on respiratory, autoinjectors and opthalmic markets.

Consort Medical CEO Jon Glenn said with programmes in autoinjectors, Point of Care diagnostics and now nasal applications, Bespak is developing a broad suite of products in new growth markets, de-risking the portfolio.

Bespak Respiratory’s device portfolio includes Medical Check Valves, Valves & Actuators, Dose Counting Actuators and Customer Devices.

The company’s Injectables’ device technology portfolio includes single-use, disposable auto injectors and reusable needle-free jet injectors.